Skip to main content

Table 1 Patient and tumor characteristics according to treatment type BCS and BCSR stages 0-II breast cancer 2007–2012 in metropolitan Detroit area (SEER)

From: A Bayesian network and heuristic approach for systematic characterization of radiotherapy receipt after breast-conservation surgery

  Breast-conservation surgery   Breast-conservation surgery  
  without radiotherapy (BCS)   with radiotherapy (BCSR)  
Variable No Row%   No Row% Total
All Patients 2517 (21.4)   9219 (78.6) 11736
Race/Ethnicity (R)
 White 1860 (21.0)   7007 (79.0) 8867
 Black 603 (23.5)   1964 (76.5) 2567
 Other 37 (16.6)   186 (83.4) 223
 Unknown 17 (21.5)   62 (78.5) 79
Age at diagnosis (A)
 ≤25 2 (40.0)   3 (60.0) 5
 26−50 480 (20.7)   1843 (79.3) 2323
 51−75 1279 (17.3)   6096 (82.7) 7375
 >75 756 (37.2)   1276 (62.8) 2032
 Unknown 0 (0.0)   1 (100.0) 1
Marital status (M)
 Single 347 (22.9)   1168 (77.1) 1515
 Married 1145 (18.6)   5022 (81.4) 6167
 Separated 19 (24.4)   59 (75.6) 78
 Divorced 228 (18.8)   982 (81.2) 1210
 Widowed 507 (30.4)   1161 (69.6) 1668
 Unmarried 0 (0.0)   2 (100.0) 2
 Unknown 271 (24.7)   825 (75.3) 1096
Insurance status (IN)
 Uninsured 24 (21.6)   87 (78.4) 111
 Medicaid 156 (25.5)   456 (74.5) 612
 Insured 2277 (21.0)   8573 (79.0) 10850
 Unknown 60 (36.8)   103 (63.2) 163
Year (Y)
 2007 491 (25.5)   1433 (74.5) 1924
 2008 440 (23.5)   1433 (76.5) 1873
 2009 434 (22.5)   1494 (77.5) 1928
 2010 340 (18.5)   1500 (81.5) 1840
 2011 417 (20.6)   1607 (79.4) 2024
 2012 395 (18.4)   1752 (81.6) 2147
AJCC Stage (S)
 0 1123 (33.5)   2230 (66.5) 3353
 I 826 (15.2)   4613 (84.8) 5439
 IIA 413 (19.1)   1752 (80.9) 2165
 IIB 155 (19.9)   624 (80.1) 779
Grade
 I 519 (18.5)   2290 (81.5) 2809
 II 787 (17.0)   3848 (83.0) 4635
 III 534 (16.9)   2633 (83.1) 3167
 IV 10 (21.7)   36 (78.3) 46
 Undetermined 667 (61.8)   412 (38.2) 1079
Tumor size (TS)a
 ≤5 434 (24.7)   1326 (75.3) 1760
 6−11 481 (16.3)   2478 (83.7) 2959
 12−17 422 (16.3)   2161 (83.7) 2583
 18−23 272 (18.2)   1223 (81.8) 1495
 24−29 173 (20.4)   674 (79.6) 847
 30−35 119 (20.3)   466 (79.7) 585
 36−41 62 (24.1)   195 (75.9) 257
 42−47 27 (20.0)   108 (80.0) 135
 48−53 36 (32.1)   76 (67.9) 112
 54−59 16 (38.1)   26 (61.9) 42
 60−65 10 (35.7)   18 (64.3) 28
 66−71 5 (29.4)   12 (70.6) 17
 72−77 4 (36.4)   7 (63.6) 11
 78−83 3 (33.3)   6 (66.7) 9
 84−89 9 (81.8)   2 (18.2) 11
 90−95 0 (0.0)   4 (100.0) 4
 96−101 4 (57.1)   3 (42.9) 7
 >101 5 (55.6)   4 (44.4) 9
 Unknown 435 (50.3)   430 (49.7) 865
Histology (H)b
 8201 97 (24.0)   307 (76.0) 404
 8211 24 (26.7)   66 (73.3) 90
 8230 41 (15.5)   223 (84.5) 264
 8480 39 (20.7)   149 (79.3) 188
 8500 1212 (16.7)   6026 (83.3) 7238
 8501 38 (13.7)   240 (86.3) 278
 8503 25 (25.5)   73 (74.5) 98
 8507 22 (25.9)   63 (74.1) 85
 8520 639 (53.7)   551 (46.3) 1190
 8522 78 (16.2)   403 (83.8) 481
 8523 215 (19.1)   909 (80.9) 1124
 Other 87 (29.4)   209 (70.6) 296
Behavior (B)
 In situ 1120 (33.5)   2224 (66.5) 3344
 Invasive 1397 (16.6)   6995 (83.4) 8392
Willingness/radiotherapy (W)c
 Not declined 2423 (20.8)   9219 (79.2) 11642
 Declined 94 (100.0)   0 (0.0) 94
Primary Site (P)
 C500 21 (32.3)   44 (67.7) 65
 C501 147 (25.5)   429 (74.5) 576
 C502 269 (19.6)   1101 (80.4) 1370
 C503 151 (20.6)   581 (79.4) 732
 C504 849 (18.8)   3668 (81.2) 4517
 C505 162 (19.0)   689 (81.0) 851
 C506 16 (25.0)   48 (75.0) 64
 C508 539 (20.9)   2038 (79.1) 2577
 C509 363 (36.9)   621 (63.1) 984
Degree/invasiveness (I)d
 F0 541 (18.8)   2342 (81.2) 2883
 F10 1119 (33.5)   2223 (66.5) 3342
 F20 779 (15.5)   4255 (84.5) 5034
 F30 26 (15.8)   139 (84.2) 165
 F40 8 (13.6)   51 (86.4) 59
 F50 15 (19.5)   62 (80.5) 77
 F60 1 (100.0)   0 (0.0) 1
 F987 28 (16.0)   147 (84.0) 175
  1. aTumor size is measure in ml
  2. bICD-O-3 Nomenclature: 8201 Cribriform carcinoma in situ, 8211 Tubular adenocarcinoma, 8230 Duct carcinoma in situ, solid type, 8480 Mucinous adenocarcinoma, 8500 Intraductal carcinoma, noninfiltrating, 8501 Comedocarcinoma, non-infiltrating, 8503 Noninfiltrating intraductal papillary adenocarcinoma, 8507 Intraductal micropapillary carcinoma, 8520 Lobular carcinoma in situ, 8522 Intraductal and lobular in situ carcinoma, 8523 Infiltr. duct mixed with other types of carcinoma, in situ
  3. cWillingness radiotherapy, is based upon the field denominated “RX SUMM–RADIATION” on the SEER data, from here the option of Patient refused radiation therapy were considered as “Declined"
  4. dDegree of tumor invasiveness was categorized with the field CS Site-Specific Factor 6 from SEER. The field records the code that indicates how the pathological tumor size was coded in tumor size. codification includes the levels: F0 Where the entire tumor reported as invasive, F10 Entire tumor reported as in situ, F20 Invasive and in situ components present (size of invasive component stated and coded in tumor size), F30 Invasive and in situ components present (size of entire tumor coded in tumor size because size of invasive component not stated and in situ described as minimal), F40 Invasive and in situ components present (size of entire tumor coded in tumor size because size of invasive component not stated and in situ described as extensive), F50 Invasive and in situ components present (size of entire tumor coded in tumor size because size of invasive component not stated and proportions of in situ and invasive not known), F60 Invasive and in situ components present (unknown tumor size coded), F987 Unknown if invasive and in situ components present